# Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma

> **NCT01757171** · PHASE2 · COMPLETED · sponsor: **Weill Medical College of Cornell University** · enrollment: 85 (actual)

## Conditions studied

- Gastric Adenocarcinoma
- Gastroesophageal Adenocarcinoma
- Distal Esophageal Adenocarcinoma

## Interventions

- **DRUG:** Cabazitaxel

## Key facts

- **NCT ID:** NCT01757171
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2016-07
- **Final completion:** 2017-06
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2018-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01757171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01757171, "Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01757171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*